Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A new study finds that a small-molecule inhibitor of IRAK4 blocks inflammation and pathophysiological processes in rheumatoid arthritis and systemic lupus erythematosus.
A study in Genome Biology reports the fine-mapping of rheumatoid arthritis risk loci in synovial fibroblasts and provides evidence of a causal role for these cells in the heritability of this disease.
A study of human immune-cell populations has shown that IFNγ from synovial natural killer cells can activate a subset of pro-inflammatory HLA-DR+CD90+ synovial fibroblasts that is greatly expanded in rheumatoid arthritis.
Targeted nanoparticles that bind to exposed type II collagen in injured joints and promote localized downregulation of Mmp13 expression represent progress towards a disease-modifying osteoarthritis drug.
A population of FOXP3+ regulatory T cells that express RANKL are capable of promoting osteoclast formation and accelerate bone loss in a mouse model of arthritis.
New research shows that metabolic modulation can restore immune tolerance induction by anti-CD45RB antibodies in lupus-prone mice and reduce systemic lupus erythematosus-like pathology.
Chimeric antigen receptor (CAR) T cell therapy has been used to treat a patient with systemic lupus erythematosus, marking the first time this approach has been successfully used to treat an autoimmune disease.
A study published in Nature shows the effects of ageing on skeletal stem cells (SSCs) and how aged SSCs affect haematopoiesis, bone turnover and fracture repair.
New research demonstrates that antibodies from patients with fibromyalgia induce sensory hypersensitivities in recipient mice, suggesting an autoimmune basis for the disease as well as new therapeutic possibilities.
An anti-CD38 monoclonal antibody and an in vivo gene-editing approach show promise for the treatment of different forms of systemic amyloidosis in separate clinical trials.
New research shows that combination therapy for septic arthritis in mice considerably reduces intracellular bacteria in synovial tissue and protects against joint damage.
New research shows that platelets inhibit regulatory T cell immunosuppressive activity in systemic lupus erythematosus via P-selectin–PSGL1 interaction.